Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Medullary 1Advanced Cancer 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Ranitidine × Clear all
NCT01287520 2019-02-25

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
41 enrolled 28 charts

Advanced Cancer

NCT01539655 2017-05-02

Vandetanib

Sanofi

Phase 1 Completed
34 enrolled

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡